Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older.
- You must have a confirmed diagnosis of a solid tumor cancer that has spread, cannot be surgically removed, or is locally advanced.
- Your cancer must have at least one area that can be measured on a scan, according to standard medical guidelines.
- You must be in generally good physical condition and able to carry out normal daily activities with little or no limitation (confirm with trial site).
- For one specific part of the trial (Part 2A only): you must have ovarian cancer with a specific genetic change called CCNE1 amplification (confirm with trial site).
Who may not be able to join:
- You may not be eligible if your cancer has actively spread to the brain.
- You may not be eligible if you have significant heart problems or reduced heart function.
- You may not be eligible if you have a bleeding disorder or have had a serious bleeding episode in the past 3 months.
- You may not be eligible if you have moderate or severe nerve damage causing symptoms such as numbness, tingling, or pain in your hands or feet.
- There are additional eligibility requirements not listed here that the trial team will review with you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Dose Limiting Toxicities (DLTs); Number of Participants With Adverse Events (AEs); Number of Participants With Serious Adverse Events (SAEs); Number of Participants With AEs Leading to Discontinuation; Number of Participants With TEAEs Leading to Death
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.